secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOLIFE SOLUTIONS INC (BLFS)
CIK:        0000834365
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001628280-23-038225
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioLife Solutions Q3 revenue falls 18% YoY; net loss widens to $29.1M on $15.5M impairment
--------------------------------------------------------------------------------

- Total revenue $33.3M, down 18% YoY; ex-COVID revenue down 10%.
- GAAP net loss $29.1M ($0.67 EPS) vs $10.3M loss in Q3 2022; includes $15.5M non-cash impairment.
- Biostorage and Services ex-COVID revenue grew 50% YoY; cell processing revenue down 26%.
- Cash $42.2M at quarter end; raised $10.4M via share sale in October 2023.
- FY2023 revenue guidance narrowed to low end of $144-158M; freezer divestiture expected in early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/834365/000162828023038225/0001628280-23-038225-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/834365/000162828023038225/blfs-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-038225

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer